Sign in

    Junwoo Park • Roth MKM

    Junwoo Park's questions to Sanara Medtech Inc (SMTI) leadership

    Junwoo Park's questions to Sanara Medtech Inc (SMTI) leadership • Q1 2025

    Question

    Junwoo Park, on for Ross Osborn, asked for guidance on gross margin cadence for the remainder of 2025 and inquired about the success metrics for the Tissue Health Plus pilot program.

    Answer

    Executive Ronald Nixon addressed gross margins, noting a recent benefit from a technology acquisition but advising to model margins consistent with the past, as significant further leverage is not expected. Executive Suresh Muppalla detailed the three categories of success metrics for the pilot: clinician-facing (protocol adherence), operational (staff productivity, cost reduction), and adoption (user satisfaction surveys).

    Ask Fintool Equity Research AI

    Junwoo Park's questions to Neuropace Inc (NPCE) leadership

    Junwoo Park's questions to Neuropace Inc (NPCE) leadership • Q4 2024

    Question

    Matthew Park, on for Ross Osborn at Cantor Fitzgerald, asked about the site of service dynamics for the potential pediatric indication, questioning if procedures would be concentrated in Level 4 centers or see broader adoption. He also inquired about NeuroPace's manufacturing capacity for 2026 and beyond given the expanding market opportunity.

    Answer

    Executive Joel Becker explained that the site of service for pediatric patients would be determined by epilepsy type, not age. Focal epilepsy patients requiring Phase II monitoring would likely be treated in Level 4 centers, while generalized epilepsy patients could be treated in Level 3 or community centers. Regarding manufacturing, he stated concisely that NeuroPace is in 'good shape from a capacity perspective' and is 'ready to go.'

    Ask Fintool Equity Research AI

    Junwoo Park's questions to Cerus Corp (CERS) leadership

    Junwoo Park's questions to Cerus Corp (CERS) leadership • Q3 2024

    Question

    Junwoo Park of Roth MKM inquired about the need for additional manufacturing capacity for the INTERCEPT Fibrinogen Complex (IFC) following new BLA approvals and the approval and replacement timeline for the new LED illuminator.

    Answer

    COO Vivek Jayaraman stated that Cerus will continue to add manufacturing partners to meet growing IFC demand. President and CEO Obi Greenman added that the LED illuminator is targeted for a 2025 European launch, with a U.S. submission likely in the 2026 timeframe, serving as a new foundational platform for the business.

    Ask Fintool Equity Research AI